Barinthus Biotherapeutics (BRNS) Non Operating Income (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Non Operating Income came in at $525000.0 in Q1 2026, down 42.93% YoY from $920000.0 in Q1 2025, and up 29.63% on a QoQ basis from $405000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Non Operating Income (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Non Operating Income data on file, last reported at $525000.0 in Q1 2026.
- Quarterly Non Operating Income fell 42.93% year-over-year to $525000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 44.07% YoY) and the FY2025 annual result came in at $3.9 million, down 41.84% from the prior year.
- Non Operating Income advanced to $525000.0 in Q1 2026, from $405000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $2.8 million in Q4 2024 to a low of $311000.0 in Q3 2022.
- A 5-year average of $1.4 million and a median of $1.4 million in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 347.59% — and 2025, when it plunged 85.55%.
- Tracing BRNS's Non Operating Income over 5 years: stood at $1.9 million in 2022, then fell by 1.73% to $1.9 million in 2023, then surged by 49.2% to $2.8 million in 2024, then sank by 85.55% to $405000.0 in 2025, then advanced by 29.63% to $525000.0 in 2026.
- The last three Non Operating Income figures came in at $525000.0 (Q1 2026), $405000.0 (Q4 2025), and $424000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 397,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 397,000.00 |
| Mar 31, 2026 | 525,000.00 |
| Dec 31, 2025 | 405,000.00 |
| Sep 30, 2025 | 424,000.00 |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 920,000.00 |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | 2.75 Mn |
| Dec 31, 2022 | 1.91 Mn |
| Sep 30, 2022 | 311,000.00 |
| Jun 30, 2022 | 1.54 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.53 Mn |
| Sep 30, 2021 | 959,000.00 |